ALXO

ALX Oncology Holdings Inc.
CAPPED RATING

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.

ALX Oncology Holdings Inc. (ALXO) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (D).

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
C
Factor Score 2.4 / 5.0
Momentum
D
Factor Score 1.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.9
EV / EBITDA -0.2
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -51.9%
Price Return 12M -18.0%
Catalyst Signal 0.00
Market Cap $138.3M
TTM Revenue N/A
Price / Sales N/A
ROE -80.6%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C+ (2.5) D+ (1.8) C (2.4) D (1.3) C+ (2.6) C- (2.1)
2026-11-10 C+ (2.5) C- (1.9) C (2.4) D+ (1.7) C+ (2.6) C (2.2)
2026-11-03 C+ (2.5) D+ (1.8) C (2.5) D+ (1.6) C+ (2.7) C (2.2)
2026-10-27 C+ (2.5) C- (1.9) C (2.5) D+ (1.6) C+ (2.6) C (2.2)
2026-10-20 C+ (2.5) D+ (1.8) C (2.5) C- (1.9) C+ (2.6) C (2.3)
Page 1 of 4